Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04988152 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

A Phase 1 study, sponsored by Vir Biotechnology.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT04988152: Completed Phase 1 study, sponsored by Vir Biotechnology.

NCT04988152 is a Phase 1 study that has completed, run by Vir Biotechnology. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04988152, a Phase 1 study, has completed, sponsored by Vir Biotechnology.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

This is a Phase I single-dose study to investigate the pharmacokinetics, safety, and tolerability of sotrovimab vs placebo by intravenous or intramuscular administration in healthy Japanese and Caucasian participants.

Primary Outcome

The Cmax was summarized using standard non-compartmental pharmacokinetic analysis methods. The geometric means and geometric coefficient of variation are presented. An ethnicity comparison (Japanese versus Caucasian) was also conducted using analysis of covariance (ANCOVA) adjusting for body weight. The geometric Least Square (LS) means ratio (Japanese versus Caucasian) for Cmax and 90 percent (%) confidence interval (CI) are presented.

Interventions

  • BIOLOGICAL sotrovimab
  • OTHER Placebo to Biologic

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2021-07-06
Est. Completion 2021-12-07
Phase Phase 1
Vir Biotechnology

13 total trials

What the finished NCT04988152 record still lists

NCT04988152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 2 interventions - of which sotrovimab is the first listed.

NCT04988152 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04988152 about?

NCT04988152 is a clinical study titled "A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants". This is a Phase I single-dose study to investigate the pharmacokinetics, safety, and tolerability of sotrovimab vs placebo by intravenous or intramuscular administration in healthy Japanese and Caucasian participants.

What is the current status of trial NCT04988152?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-07-06. Estimated completion is 2021-12-07.

What interventions are being tested in trial NCT04988152?

The interventions under investigation include: sotrovimab (BIOLOGICAL), Placebo to Biologic (OTHER).

Who is sponsoring clinical trial NCT04988152?

This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04988152's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04988152, the US trial registry maintained by the National Library of Medicine. NCT04988152 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.